Company / Accounts Receivable
Sarepta Therapeutics Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$398.2M
FY2025
5-year range
$153.0M / $602.0M
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
#25 of 113
Health Care
What the data says
Sarepta Therapeutics's accounts receivable of $398M is higher than 78% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
$398M in FY2025 with a 5-year CAGR of +31.5%. Top quartile in the Health Care sector.
Remained stable around $398M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- +31.5%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 113This company $398.2M Sector average $1.1B
▼
-65.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.5%, indicating consistent growth.
- In FY2025, accounts receivable decreased 33.8% year-over-year.
- Ranks #25 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $398.2M | -33.8% |
| FY2024 | $602.0M | +50.4% |
| FY2023 | $400.3M | +86.5% |
| FY2022 | $214.6M | +40.3% |
| FY2021 | $153.0M | +51.0% |
| FY2020 | $101.3M | +11.5% |
| FY2019 | $90.9M | +85.3% |
| FY2018 | $49.0M | +66.4% |
| FY2017 | $29.5M | +463.7% |
| FY2016 | $5.2M | +31.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026